What drug is Kanamab (Ilaris)
Kanamab (Ilaris) is a humanized monoclonal antibody that belongs to selective IL-1 β inhibitors. It is mainly used to treat various autoimmune inflammatory diseases by specifically blocking the inflammatory factor IL-1 β.
1. Basic information of the drug
(1) Common name: canakinumab
(2) Product Name: Ilaris
(3) R&D company: Novartis, Switzerland
(4) Approval time: First approved by FDA for CAPS treatment in 2009
2 Pharmacological mechanism of action
(1) Target effect: High affinity binding to free IL-1 β, blocking its interaction with IL-1 receptors
(2) Effect pathway: Inhibit downstream inflammatory signaling pathways, including NF - κ B and MAPK pathways
(3) Biological effect: Reduce C-reactive protein (CRP) and serum amyloid A (SAA) levels
3 main treatment areas
(1) Periodic fever syndrome: CAPS, FMF, TRAPS, etc
(2) Other indications: Systemic juvenile idiopathic arthritis (SJIA), gouty arthritis
(3) Extended study: Cardiovascular field (CANTOS trial) shows anti-inflammatory effects
4 Drug characteristics
(1) Molecular type: IgG1/κ monoclonal antibody
(2) Molecular weight: approximately 145kDa
(3) Half life: 26 days (supports dosing regimen every 8 weeks)
(4) Administration route: Subcutaneous injection
Disclaimer：《What drug is Kanamab (Ilaris)》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！